{"id":"spacing-of-eculizumab-infusions","safety":{"commonSideEffects":[{"rate":null,"effect":"Meningococcal infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Eculizumab is a monoclonal antibody that binds to complement protein C5, preventing its cleavage and blocking the formation of the membrane attack complex (C5a and C5b-9). By inhibiting terminal complement activation, it reduces inflammation and cell lysis in complement-mediated diseases. This Phase 3 trial examines whether spacing infusions further apart maintains disease control compared to standard dosing schedules.","oneSentence":"This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:41.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"Atypical hemolytic uremic syndrome (aHUS)"},{"name":"Generalized myasthenia gravis (gMG)"},{"name":"Neuromyelitis optica spectrum disorder (NMOSD)"}]},"trialDetails":[{"nctId":"NCT04859608","phase":"PHASE3","title":"Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2021-10-20","conditions":"Hemolytic-Uremic Syndrome, Atypical","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Spacing of Eculizumab infusions","genericName":"Spacing of Eculizumab infusions","companyName":"University Hospital, Tours","companyId":"university-hospital-tours","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}